A phase IIb, multicenter, randomized, double-blind, placebo controlled study to evaluate the safety, clinical efficacy and joint damage protection of two different doses of BMS-188667 [abatacept] using two dose schedules administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate

Trial Profile

A phase IIb, multicenter, randomized, double-blind, placebo controlled study to evaluate the safety, clinical efficacy and joint damage protection of two different doses of BMS-188667 [abatacept] using two dose schedules administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2014

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jul 2010 According to a BMS media release, European Commission has approved abatacept in combination with methotrexate for earlier use as first-line biologic after DMARD inadequate response for treatment of rheumatoid arthritis.
    • 26 May 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top